Envafolimab plus chemo for esophageal cancer before surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug (Envafolimab) combined with standard chemotherapy before surgery for esophageal cancer that has not spread far. The goal is to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with esophageal squamous cell carcinoma that can be removed by surgery.
- Your cancer is at a specific stage (T2-4aNxM0) and your doctor recommends treatment before surgery.
- You are at least 18 years old and in good physical condition (ECOG score 0 or 1).
- You have not had any prior immunotherapy, chemotherapy, targeted therapy, or radiation for this cancer.
- You do not have active autoimmune diseases or other serious uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests a new immunotherapy drug (ivonescimab, also called AK112) combined with chemotherapy before surgery for people with esophageal squamous cell cancer that can be completely removed. The goal is to see if adding immunotherapy before surgery helps shrink the tumor and improve outcomes.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.